Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06021197
PHASE2

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

Sponsor: China Medical University Hospital

View on ClinicalTrials.gov

Summary

Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.

Official title: NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Patients During Symptomatic Remission

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2023-10-12

Completion Date

2028-03

Last Updated

2025-02-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

NMDAE

Use of an NMDA enhancer for the treatment of CIAS

DRUG

Placebo Cap

Use of placebo as a comparator

Locations (1)

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan